Key statistics
On Thursday, Abeona Therapeutics Inc (ABEO:NAQ) closed at 5.79, 89.84% above the 52 week low of 3.05 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.79 |
---|---|
High | 5.99 |
Low | 5.62 |
Bid | 5.50 |
Offer | 6.27 |
Previous close | 5.75 |
Average volume | 416.90k |
---|---|
Shares outstanding | 43.31m |
Free float | 41.09m |
P/E (TTM) | -- |
Market cap | 250.79m USD |
EPS (TTM) | -2.29 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
- Abeona Therapeutics® Reports Third Quarter 2024 Financial Results and Recent Corporate Updates
- Abeona Therapeutics® Announces FDA Acceptance of BLA Resubmission of Pz-cel for the Treatment of Recessive Dystrophic Epidermolysis Bullosa
- Abeona Therapeutics® Announces Participation in November Investor Conferences
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Abeona Therapeutics® Completes Pz-cel Biologics License Application Resubmission to U.S. Food and Drug Administration
- Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences
- Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors
- Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel
- Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission
- Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications
More ▼